Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say

The European Medicines Agency (EMA) has concluded that non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may cause vision loss, is a very rare side effect of semaglutide (Ozempic, Rybelsus, and Wegovy), estimating it may affect up to 1 in 10,000 users; the agency will update product information to reflect this risk. Separately, a study published in JAMA Ophthalmology indicates that GLP-1 receptor agonists, including semaglutide, may significantly increase the risk of neovascular age-related macular degeneration (nAMD) in older diabetic patients, based on an analysis of over 1 million Ontario residents with diabetes.

Analysis

The European Medicines Agency (EMA) has concluded its review of Novo Nordisk's (NVO) semaglutide-containing medicines (Ozempic, Rybelsus, Wegovy), classifying non-arteritic anterior ischemic optic neuropathy (NAION) as a "very rare" side effect, estimated to affect up to 1 in 10,000 users; product information will be updated accordingly. This decision acknowledges epidemiological data suggesting an approximate two-fold increased NAION risk in adults with type 2 diabetes using semaglutide, corresponding to roughly one additional case per 10,000 person-years of treatment, and a slightly higher risk observed in clinical trials versus placebo. Concurrently, separate research published in JAMA Ophthalmology indicates a potentially more concerning development: GLP-1 receptor agonists, with semaglutide being predominant in the study cohort of over 1 million Ontario residents with diabetes, may significantly increase the risk of neovascular age-related macular degeneration (nAMD) in older diabetic patients. These ophthalmological findings, particularly the nAMD risk, contribute to a moderately negative sentiment (-0.6 for NVO specifically) and a cautious outlook, signaling potential challenges for this widely used drug class despite the EMA's 'very rare' NAION classification.

Key Decisions for Investors

• Investors should closely monitor Novo Nordisk's (NVO) sales data and physician prescribing patterns for semaglutide products in light of the NAION labeling update and the emerging nAMD risk information.
• Consider the potential for increased regulatory oversight or future litigation related to these ocular adverse events, which could impact long-term growth forecasts and profitability for NVO.
• Re-evaluate NVO's risk-reward profile, assessing whether current market valuations adequately discount these ophthalmological safety signals, especially concerning the nAMD risk in the significant older diabetic patient population.